Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 93.6 Cr.
- Current Price ₹ 175
- High / Low ₹ 310 / 170
- Stock P/E 11.7
- Book Value ₹ 66.2
- Dividend Yield 0.00 %
- ROCE 35.2 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 136 days to 85.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 17.80 | 61.73 | 83.19 | |
| 15.54 | 52.85 | 71.70 | |
| Operating Profit | 2.26 | 8.88 | 11.49 |
| OPM % | 12.70% | 14.39% | 13.81% |
| 0.03 | 0.08 | 0.08 | |
| Interest | 0.09 | 0.21 | 0.55 |
| Depreciation | 0.01 | 0.02 | 0.03 |
| Profit before tax | 2.19 | 8.73 | 10.99 |
| Tax % | 27.85% | 27.49% | |
| 1.59 | 6.33 | 8.02 | |
| EPS in Rs | 3.24 | 12.74 | 15.56 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 152% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 |
| Reserves | 13.32 | 22.77 | 30.04 |
| 1.60 | 3.26 | 6.87 | |
| 0.96 | 4.57 | 9.25 | |
| Total Liabilities | 20.78 | 35.57 | 51.51 |
| 0.05 | 1.65 | 1.73 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.42 | 0.43 | 0.43 |
| 20.31 | 33.49 | 49.35 | |
| Total Assets | 20.78 | 35.57 | 51.51 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.87 | 1.21 | |
| -0.52 | -1.56 | |
| 13.13 | 2.86 | |
| Net Cash Flow | 8.74 | 2.50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 66.03 | 86.09 |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 66.03 | 86.09 |
| Working Capital Days | 186.81 | 85.56 |
| ROCE % | 35.18% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
2d - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for your reference.
-
Announcement under Regulation 30 (LODR)-Allotment
17 Dec - Allotment of 392,000 preferential warrants at Rs.251 each (Rs98,392,000) on 17-Dec-2025; 25% paid; convertible within 18 months.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E., On 17Th December, 2025 As per Regulation 30 Of The SEBI (LODR) Regulations, 2015
17 Dec - Allotment of 3,92,000 warrants at ₹251 each totalling ₹9,83,92,000 on 17 Dec 2025.
-
Intimation Of Receipt Of Tender Awarded By Central Procument Agency Delhi- Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI Listing Regulations') By TTG Innovations Private Limited (The 'Company')
16 Dec - TTG Innovations awarded 2-year DGHS sutures supply tender; sales may rise up to ₹100 crore.
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
20 Nov 2025 - BSE issued 'No adverse observations' on Nov 19, 2025 for merger of TTG Innovations into Royal Sense.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.